{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rovalpituzumab+tesirine", "query": { "intervention": "Rovalpituzumab tesirine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T19:55:50.461Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03026166", "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Rovalpituzumab tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2017-03-30", "completion_date": "2019-07-03", "has_results": true, "last_update_posted_date": "2020-07-17", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 15, "location_summary": "La Jolla, California • Orlando, Florida • Athens, Georgia + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03026166" }, { "nct_id": "NCT01901653", "title": "Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Small Cell Lung Cancer" ], "interventions": [ { "name": "Rovalpituzumab tesirine (SC16LD6.5)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemcentrx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2013-07", "completion_date": "2016-11-28", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01901653" }, { "nct_id": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Rovalpituzumab tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-03-15", "completion_date": "2018-12-20", "has_results": false, "last_update_posted_date": "2018-12-26", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 27, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334487" }, { "nct_id": "NCT02874664", "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Rovalpituzumab Tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemcentrx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2016-09", "completion_date": "2018-09-12", "has_results": false, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 13, "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02874664" }, { "nct_id": "NCT02709889", "title": "Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma", "Medullary Thyroid Cancer", "Glioblastoma", "Large-Cell Neuroendocrine Carcinoma", "Neuroendocrine Prostate Cancer", "High Grade Gastroenteropancreatic Neuroendocrine Carcinoma", "Other Neuroendocrine Carcinoma", "Other Solid Tumors" ], "interventions": [ { "name": "Rovalpituzumab tesirine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 200, "start_date": "2016-09-23", "completion_date": "2019-08-27", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709889" }, { "nct_id": "NCT02819999", "title": "A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Rovalpituzumab Tesirine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-10", "completion_date": "2019-05-31", "has_results": false, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 11, "location_summary": "Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02819999" }, { "nct_id": "NCT03033511", "title": "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Placebo for dexamethasone", "type": "DRUG" }, { "name": "Placebo for rovalpituzumab tesirine", "type": "DRUG" }, { "name": "Rovalpituzumab tesirine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 748, "start_date": "2017-02-07", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-07-29", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 54, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 48 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03033511" }, { "nct_id": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rovalpituzumab Tesirine", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2016-12-14", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 5, "location_summary": "La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000257" }, { "nct_id": "NCT03061812", "title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Rovalpituzumab tesirine", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2017-04-11", "completion_date": "2020-02-12", "has_results": true, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03061812" }, { "nct_id": "NCT03543358", "title": "A Long-Term Study of Rovalpituzumab Tesirine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "rovalpituzumab tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-09-10", "completion_date": "2019-11-26", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-25T19:55:50.461Z", "location_count": 3, "location_summary": "Tucson, Arizona • Duarte, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543358" } ] }